Role of Tcl1 and Par-4 in regulation of chronic lymphocytic leukemia

描述（由申请人提供）：慢性淋巴细胞白血病（CLL），也称为小细胞淋巴瘤，占所有非霍奇金淋巴瘤病例的近30%。这是最常见的成人白血病。尽管化疗取得了进展，但CLL患者的治疗选择有限，仅具有适度的疗效，特别是对于具有未突变类型的B细胞受体（BCR）、del（17 p13.1）和p53突变的患者。Tcl-1是一种癌基因，最初发现在T细胞白血病中发生易位，现已发现在被归类为侵袭性的CLL表型中表达水平更高。通过使用免疫球蛋白启动子和E？增强子在B细胞中表达Tcl-1癌基因，已经产生了CLL的小鼠模型。这些小鼠在13-18个月内可重复地发展CLL，并且已被证明是人类CLL的优良模型。Par-4是我们发现的一种促凋亡肿瘤抑制因子，它通过Fas途径和抑制NF-κ B诱导肿瘤细胞凋亡，但不诱导正常细胞凋亡。B。我们做了四个新的观察。首先，如Src家族蛋白酪氨酸激酶（SFK）的组成性激活所反映的，B细胞受体信号传导途径在人CLL细胞和CLL的E-Tcl-1小鼠模型中都是活跃的。第二，我们发现Tcl 1的表达在SFK抑制后下调，这表明BCR信号在Tcl 1表达中的作用。第三，我们发现与正常小鼠相比，Par-4在E <$-Tcl 1 CLL细胞中的表达下调，而其在人CLL细胞中的表达是可变的。第四，我们发现E-Tcl 1细胞被可溶性Par-4和SAC杀死，SAC是Par-4的一个特异性结构域，仅对肿瘤细胞具有细胞毒性。基于这些观察结果，我们假设Tcl 1和Par-4之间的平衡调节BCR信号决定的生存和死亡之间的CLL细胞的命运。我们有三个具体目标。目标1将使用E ²-Tcl-1 CLL小鼠模型确定BCR信号传导的重要性以及特定SFK在调节Tcl-1和Par-4表达中的作用。目的2：利用新建立的诱导型Par-4转基因小鼠模型和E <$-Tcl-1小鼠研究Par-4过表达对CLL发生的重要性。目标2将涉及临床前研究，以测试细胞外Par-4和SAC在E-Tcl-1小鼠模型中抑制CLL生长的功效。在目标3中，将使用来自患者的原代CLL细胞研究Tcl-1和Par-4的相对重要性，从而将目标1和2中的基础研究结果转化为临床样品。英国和俄勒冈州立大学之间的合作为我们提供了一个机会，将前两个目标的基础科学和临床前发现与使用患者来源的CLL细胞的目标3的研究相结合。这些研究的令人兴奋的方面是可溶性Par-4或SAC可以单独或与SFK抑制剂或我们实验室目前正在研究的其他靶点组合开发成CLL细胞的治疗策略的可能性。

DESCRIPTION (provided by applicant): Chronic lymphocytic leukemia (CLL), also known as small cell lymphoma, constitutes almost 30% of all cases of non-Hodgkin's lymphoma. It is the most common adult leukemia. Despite advances in chemotherapy, treatment options for CLL patients are limited with only a modest efficacy, especially for patients with unmutated types of B cell receptors (BCR), del (17p13.1) and p53 mutations. Tcl-1, an oncogene, initially found to be translocated in T-cell leukemias, has been found to be expressed at higher levels in CLL phenotypes that are classified as aggressive. A mouse model for CLL has been generated by expressing the Tcl-1 oncogene in B cells using immunoglobulin promoter and the E¿ enhancer. These mice reproducibly develop CLL in 13-18 months and have been shown to be excellent models for human CLL. Par-4 is a pro-apoptotic tumor suppressor, discovered by us, that induces apoptosis in cancer but not normal cells using both the Fas pathway and by inhibiting NF-?B. We made four novel observations. First, the B-cell receptor signaling pathway is active both in the human CLL cells and in the E¿-Tcl-1 mouse model of CLL as reflected by constitutive activation of Src family protein tyrosine kinases (SFK). Second, we discovered that expression of Tcl1 is down regulated upon inhibition of SFK suggesting a role for BCR signaling in Tcl1 expression. Third we found that expression of Par-4 is down-regulated in E¿-Tcl1 CLL cells compared to normal mice, while its expression has been found to be variable in human CLL cells. Fourth we discovered that E¿-Tcl1 cells are killed by soluble Par-4 and SAC, a specific domain of Par-4 that is cytotoxic only to tumor cells. Based on these observations we hypothesize that a balance between Tcl1 and Par-4 regulated by BCR signaling decides the fate of CLL cells between survival and death. We have three specific aims. Aim 1 will determine the importance of BCR signaling and the role of specific SFKs in the regulation of Tcl-1 and Par-4 expression using the E¿-Tcl-1 mouse model of CLL. Aim 2 will investigate the importance of Par-4 overexpression for CLL development using a newly generated inducible Par-4 transgenic mice mouse model and the E¿-Tcl-1 mice. Aim 2 will involve preclinical studies to test the efficacy of extracellular Par-4 and SAC to inhibit CLL growth in the E¿-Tcl-1 mouse model. The relative importance of Tcl-1 and Par-4 will be studied in Aim 3 with primary CLL cells from patients, thus translating the basic research findings in Aims 1 and 2 to clinical samples. The collaboration between UK and OSU provides us an opportunity to integrate the basic science and pre-clinical findings from the first two Aims with studies in Aim 3 using patient derived CLL cells. The exciting aspect of these studies is the possibility that soluble Par-4 or SAC can be developed into a treatment strategy for CLL cells either in isolation or in combination with SFK inhibitors or other targets that are currently being investigated in our laboratories.